The in+care Campaign is a multi-year effort managed by the National Quality Center and sponsored by the Health Resources Services Administration HIV/AIDS Bureau. It is designed to bring together local, regional and national organizations that are focused on improving patient retention in HIV care. in+care kicked off in October 2011 and has enrolled more than 700 individual HIV providers representing more than 500 provider organizations, including Ryan White grantees and subgrantees of all Parts funding.
How many of you are currently reading this blog on your phones? Wait! Don’t answer that. Just the fact that you are reading this and not playing Bejeweled means we are off to a great start. However, if you are using your cell phone to access the internet, you aren’t alone. As of May 2013, 85% of U.S. adults are online, 91% have a cell phone and 56% have a smartphone. Along with increased smartphone ownership, the use of mobile phone applications or ‘apps’ is on the rise.
In January 2013, the AIDS Education and Training Center National Resource Center (AETC NRC) hosted the training exchange Guidelines for Improving Entry Into and Retention in Care and ARV Adherence for Persons with HIV. This training exchange featured presentations on the latest evidence-based recommendations for improving entry into, retention in care, and medication adherence for persons living with HIV infection.
Two goals of the National HIV/AIDS Strategy, reducing HIV incidence, and increasing access to care/optimizing outcomes, can be strongly and positively affected by engaging and retaining HIV-infected patients in clinical care. Why has this been so challenging? A glance at the Spectrum of Engagement in Care Cascade shows dramatic decreases from the number of people diagnosed with HIV to those engaged in clinical care, taking antiretroviral therapy, and achieving undetectable viral loads.
With only about one-quarter of Americans living with HIV being virally suppressed, more Americans becoming newly infected each year, and an aging cohort of HIV specialty care providers (who started providing care to HIV infected persons in the 1980’s), it is essential that health professional training programs incorporate curricula and experience regarding HIV prevention, diagnosis, care, and treatment.
Cobicistat is a derivative of ritonavir and a potent inhibitor of CYP3A. As does ritonavir, it "boosts" blood levels of other substrates of this enzyme but, unlike ritonavir, it has no activity against HIV. It has been developed as a pharmacokinetic enhancer of the integrase inhibitor elvitegravir and of some PIs.